<table>
<thead>
<tr>
<th>S. No.</th>
<th>Figures Description</th>
<th>Figure No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Kinetic growth curve of H. pylori (HP-B1) in dilution series 10-1, 10-2, and 10-3 with 107 population on BHIA supplemented with 5% sheep blood.</td>
<td>Growth Curve [1]</td>
</tr>
<tr>
<td>2.</td>
<td>Kinetic growth curve of H. pylori (HP-B2) in dilution series 10-1, 10-2, and 10-3 with 107 population on BHIA supplemented with 5% sheep blood.</td>
<td>Growth Curve [2]</td>
</tr>
<tr>
<td>3.</td>
<td>Kinetic growth curve of H. pylori (HP-B3) in dilution series 10-1, 10-2, and 10-3 with 107 population on BHIA supplemented with 5% sheep blood.</td>
<td>Growth Curve [3]</td>
</tr>
<tr>
<td>4.</td>
<td>Kinetic growth curve of H. pylori (HP-B4) in dilution series 10-1, 10-2, and 10-3 with 107 population on BHIA supplemented with 5% sheep blood.</td>
<td>Growth Curve [4]</td>
</tr>
<tr>
<td>5.</td>
<td>Time kill curve of Pantoprazole-Clarithromycin Combinations in ratio 1:12.5 in comparison with Pantoprazole and Clarithromycin in HP-B1.</td>
<td>Time Kill Curve [1]</td>
</tr>
<tr>
<td>7.</td>
<td>Time kill curve of Pantoprazole-Clarithromycin Combinations in ratio 1:12.5 in comparison with Pantoprazole and Clarithromycin in HP-B3.</td>
<td>Time Kill Curve [3]</td>
</tr>
<tr>
<td>8.</td>
<td>Time kill curve of Pantoprazole-Clarithromycin Combinations in ratio 1:12.5 in comparison with Pantoprazole and Clarithromycin in HP-B4.</td>
<td>Time Kill Curve [4]</td>
</tr>
<tr>
<td>11.</td>
<td>Time kill curve of Pantoprazole-Amoxicillin Combinations in ratio 1:12.5 in comparison with Pantoprazole and Amoxicillin in HP-B3.</td>
<td>Time Kill Curve [7]</td>
</tr>
<tr>
<td>12.</td>
<td>Time kill curve of Pantoprazole-Amoxicillin Combinations in ratio 1:12.5 in comparison with Pantoprazole and Amoxicillin in HP-B4.</td>
<td>Time Kill Curve [8]</td>
</tr>
<tr>
<td>13.</td>
<td>Time kill curve of Pantoprazole-Tetracycline Combinations in ratio 1:12.5 in comparison with Pantoprazole and Tetracycline in HP-B1.</td>
<td>Time Kill Curve [9]</td>
</tr>
<tr>
<td>15.</td>
<td>Time kill curve of Pantoprazole-Tetracycline Combinations in ratio 1:12.5 in comparison with Pantoprazole and Tetracycline in HP-B3.</td>
<td>Time Kill Curve [11]</td>
</tr>
<tr>
<td>16.</td>
<td>Time kill curve of Pantoprazole-Tetracycline Combinations in ratio 1:12.5 in comparison with Pantoprazole and Tetracycline in HP-B4.</td>
<td>Time Kill Curve [12]</td>
</tr>
<tr>
<td>17.</td>
<td>Time kill curve of Pantoprazole-Metronidazole Combinations in ratio 1:12.5 in comparison with Pantoprazole and Metronidazole in HP-B1.</td>
<td>Time Kill Curve [13]</td>
</tr>
<tr>
<td>18.</td>
<td>Time kill curve of Pantoprazole-Metronidazole Combinations in ratio 1:12.5 in comparison with Pantoprazole and Metronidazole in HP-B2.</td>
<td>Time Kill Curve [14]</td>
</tr>
<tr>
<td>19.</td>
<td>Time kill curve of Pantoprazole-Metronidazole Combinations in ratio 1:12.5 in comparison with Pantoprazole and Metronidazole in HP-B3.</td>
<td>Time Kill Curve [15]</td>
</tr>
</tbody>
</table>
20. Time kill curve of Pantoprazole-Metronidazole Combinations in ratio 1:12.5 in comparison with Pantoprazole and Metronidazole in HP-B4.


23. Time kill curve of Pantoprazole- Cefotaxime Combinations in ratio 1:12.5 in comparison with Pantoprazole and Cefotaxime in HP-B3.

24. Time kill curve of Pantoprazole- Cefotaxime Combinations in ratio 1:12.5 in comparison with Pantoprazole and Cefotaxime in HP-B4.

25. Time kill curve of Pantoprazole- Ceftazidime Combinations in ratio 1:12.5 in comparison with Pantoprazole and Ceftazidime in HP-B1.


27. Time kill curve of Pantoprazole- Ceftazidime Combinations in ratio 1:12.5 in comparison with Pantoprazole and Ceftazidime in HP-B3.

28. Time kill curve of Pantoprazole- Ceftazidime Combinations in ratio 1:12.5 in comparison with Pantoprazole and Ceftazidime in HP-B4.

29. Time kill curve of Pantoprazole- Ceftriaxone Combinations in ratio 1:12.5 in comparison with Pantoprazole and Ceftriaxone in HP-B1.

30. Time kill curve of Pantoprazole- Ceftriaxone Combinations in ratio 1:12.5 in comparison with Pantoprazole and Ceftriaxone in HP-B2.

31. Time kill curve of Pantoprazole- Ceftriaxone Combinations in ratio 1:12.5 in comparison with Pantoprazole and Ceftriaxone in HP-B3.

32. Time kill curve of Pantoprazole- Ceftriaxone Combinations in ratio 1:12.5 in comparison with Pantoprazole and Ceftriaxone in HP-B4.

33. Time kill curve of Pantoprazole- Ciprofloxacin Combinations in ratio 1:12.5 in comparison with Pantoprazole and Ciprofloxacin in HP-B1.

34. Time kill curve of Pantoprazole- Ciprofloxacin Combinations in ratio 1:12.5 in comparison with Pantoprazole and Ciprofloxacin in HP-B2.

35. Time kill curve of Pantoprazole- Ciprofloxacin Combinations in ratio 1:12.5 in comparison with Pantoprazole and Ciprofloxacin in HP-B3.

36. Time kill curve of Pantoprazole- Ciprofloxacin Combinations in ratio 1:12.5 in comparison with Pantoprazole and Ciprofloxacin in HP-B4.

37. Time kill curve of Pantoprazole- Erythromycin Combinations in ratio 1:1 in comparison with Pantoprazole and Erythromycin in HP-B1.

38. Time kill curve of Pantoprazole- Erythromycin Combinations in ratio 1:1 in comparison with Pantoprazole and Erythromycin in HP-B2.

39. Time kill curve of Pantoprazole- Erythromycin Combinations in ratio 1:1 in comparison with Pantoprazole and Erythromycin in HP-B3.
40. Time kill curve of Pantoprazole-Erythromycin Combinations in ratio 1:1 in comparison with Pantoprazole and Erythromycin in HP-B4.

41. Time kill curve of Pantoprazole- Gentamycin Combinations in ratio 1:1 in comparison with Pantoprazole and Gentamycin in HP-B1.

42. Time kill curve of Pantoprazole- Gentamycin Combinations in ratio 1:1 in comparison with Pantoprazole and Gentamycin in HP-B2.

43. Time kill curve of Pantoprazole- Gentamycin Combinations in ratio 1:1 in comparison with Pantoprazole and Gentamycin in HP-B3.

44. Time kill curve of Pantoprazole- Gentamycin Combinations in ratio 1:1 in comparison with Pantoprazole and Gentamycin in HP-B4.

45. Time kill curve of Pantoprazole-Tobramycin Combinations in ratio 1:1 in comparison with Pantoprazole and Tobramycin in HP-B1.

46. Time kill curve of Pantoprazole-Tobramycin Combinations in ratio 1:1 in comparison with Pantoprazole and Tobramycin in HP-B2.

47. Time kill curve of Pantoprazole-Tobramycin Combinations in ratio 1:1 in comparison with Pantoprazole and Tobramycin in HP-B3.

48. Time kill curve of Pantoprazole- Tobramycin Combinations in ratio 1:1 in comparison with Pantoprazole and Tobramycin in HP-B4.

49. Control stomach, s:Muscularis mucosae, m: Mucosa, u: Submucosa.

50. Infected stomach at 10 X, H: Helicobacter pylori, s: Muscularis mucosae, u: Submucosa, C: Circular layer of muscularis.


52. Infected stomach with treatment of Pantopeazole-Tetracycline, a fixed dose combination for 15 days at 10 X, H: Helicobacter pylori, s: Muscularis mucosae, u: Submucosa, N: Neutrophils, NE: Necrotic tissue.

53. Infected stomach with treatment of Pantopeazole-Tetracycline, a fixed dose combination for 30 days at 10 X, H: Helicobacter pylori, s: Muscularis mucosae, u: Submucosa, m: Mucosa.

54. Infected stomach with treatment of Pantopeazole-Tetracycline, a fixed dose combination for 45 days at 10 X, R: Regenerated mucosa.

55. Infected stomach with treatment of Pantopeazole-Tetracycline, a fixed dose combination for 60 days at 10 X, R: Regenerated mucosa.

56. Control stomach, s: Muscularis mucosae, m: Mucosa.

57. Infected stomach at 10 X, H: Helicobacter pylori, s: Muscularis mucosae, u: Submucosa, NE: Necrotic tissue.


59. Infected stomach with treatment of Pantopeazole-Clarithromycin, a fixed dose combination for 15 days at 10 X, H: Helicobacter pylori, s: Muscularis
60. Infected stomach with treatment of Pantopeazole-Clarithromycin, a fixed dose combination for 30 days at 10 X, s: Muscularis mucosae, NE: Necrotic tissue.

61. Infected stomach with treatment of Pantopeazole-Clarithromycin, a fixed dose combination for 45 days at 10 X, s: Muscularis mucosae, R: Regenerated mucosa.

62. Infected stomach with treatment of Pantopeazole-Clarithromycin, a fixed dose combination for 60 days at 10 X, s: Muscularis mucosae, R: Regenerated mucosa.

63. Control stomach, s: Muscularis mucosae, m: Mucosa, u: Submucosa.

64. Infected stomach at 10 X, H: Helicobacter pylori, m: Mucosa, u: Submucosa, N: Neutrophils, NE: Necrotic tissue.


66. Infected stomach with treatment of Pantopeazole-Amoxicillin, a fixed dose combination for 15 days at 10 X, H: Helicobacter pylori, m: Mucosa, NE: Necrotic tissue.

67. Infected stomach with treatment of Pantopeazole-Amoxicillin, a fixed dose combination for 30 days at 10 X, s: Muscularis mucosae, u: Submucosa, D: Degenerated mucosa.

68. Infected stomach with treatment of Pantopeazole-Amoxicillin, a fixed dose combination for 45 days at 10 X, R: Regenerated mucosa.

69. Infected stomach with treatment of Pantopeazole-Amoxicillin, a fixed dose combination for 60 days at 10 X, s: Muscularis mucosae, R: Regenerated mucosa.


71. Infected small intestine at 10 X, i: Helicobacter pylori infection, a: Muscularis mucosae, p: Lamina propria.

72. Infected small intestine with treatment of Pantopeazole-Tetracycline, a fixed dose combination for 15 days at 10 X, i: Helicobacter pylori infection, p: Lamina propria.

73. Infected small intestine with treatment of Pantopeazole-Tetracycline, a fixed dose combination for 30 days at 10 X, p: Lamina propria, v: Villi.

74. Infected small intestine with treatment of Pantopeazole-Tetracycline, a fixed dose combination for 45 days at 10 X, a: Muscularis mucosae, p: Lamina propria, v: Villi.

75. Infected small intestine with treatment of Pantopeazole-Tetracycline, a fixed dose combination for 60 days at 10 X, p: Lamina propria, v: Villi.

76. Control small intestine, p: Lamina propria, and v: Villi.

77. Infected small intestine at 10 X, i: Helicobacter pylori infection and p: Lamina
78. Infected small intestine with treatment of Pantopeazole-Clarithromycin, a fixed dose combination for 15 days at 10 X, p: Lamina propria, a: Muscularis mucosae.

79. Infected small intestine with treatment of Pantopeazole-Clarithromycin, a fixed dose combination for 30 days at 10 X, a: Muscularis mucosae, c: Crypts.

80. Infected small intestine with treatment of Pantopeazole-Clarithromycin, a fixed dose combination for 45 days at 10 X, a: Muscularis mucosae, p: Lamina propria.

81. Infected small intestine with treatment of Pantopeazole-Clarithromycin, a fixed dose combination for 60 days at 10 X, p: Lamina propria, a: Muscularis mucosae, v: Villi, c: Crypts.

82. Control small intestine, p: Lamina propria, and v: Villi.


84. Infected small intestine with treatment of Pantopeazole-Amoxicillin, a fixed dose combination for 15 days at 10 X, v: Villi, c: Crypts.

85. Infected small intestine with treatment of Pantopeazole- Amoxicillin, a fixed dose combination for 30 days at 10 X, a: Muscularis mucosae, v: Villi, c: Crypts.

86. Infected small intestine with treatment of Pantopeazole-Amoxicillin, a fixed dose combination for 45 days at 10 X, v: villi,Crypts.

87. Infected small intestine with treatment of Pantopeazole-Amoxicillin, a fixed dose combination for 60 days at 10 X, p: Lamina propria, a: Muscularis mucosae, v: Villi.


89. Infected Rectum at 10 X, N: Lamina propria, C: Crypt of lieberkuhn.

90. Infected Rectum with treatment of Pantopeazole-Tetracycline, a fixed dose combination for 15 days at 10 X, N: Lamina propria, M: Muscularis mucosa, and C: Crypt of lieberkuhn.

91. Infected Rectum with treatment of Pantopeazole- Tetracycline, a fixed dose combination for 30 days at 10 X, N: Lamina propria, M: Muscularis mucosa, C: Crypt of lieberkuhn, and A: Vain.

92. Infected Rectum with treatment of Pantopeazole-Tetracycline, a fixed dose combination for 45 days at 10 X, N: Lamina propria, and C: Crypt of lieberkuhn

93. Infected Rectum with treatment of Pantopeazole-Tetracycline, a fixed dose combination for 60 days at 10 X, N: Lamina propria, M: Muscularis mucosa, and C: Crypt of lieberkuhn.

95. Infected Rectum at 10 X, N: Lamina propria, M: Muscularis mucosa, C: Crypt of lieberkuhn.

96. Infected Rectum with treatment of Pantopeazole-Clarithromycin, a fixed dose combination for 15 days at 10 X, N: Lamina propria, M: Muscularis mucosa, and C: Crypt of lieberkuhn.

97. Infected Rectum with treatment of Pantopeazole-Clarithromycin, a fixed dose combination for 30 days at 10 X, N: Lamina propria, M: Muscularis mucosa, and C: Crypt of lieberkuhn.

98. Infected Rectum with treatment of Pantopeazole-Clarithromycin, a fixed dose combination for 45 days at 10 X, N: Lamina propria, and C: Crypt of lieberkuhn.

99. Infected Rectum with treatment of Pantopeazole-Clarithromycin, a fixed dose combination for 60 days at 10 X, N: Lamina propria and C: Crypt of lieberkuhn.

100. Control Rectum, N: Lamina propria, M: Muscularis mucosa, N: Lamina propria, E: Submucosa, C: Crypt of lieberkuhn, and A

101. Infected Rectum at 10 X, N: Lamina propria and C: Crypt of lieberkuhn.

102. Infected Rectum with treatment of Pantopeazole-Amoxicillin, a fixed dose combination for 15 days at 10 X, N: Lamina propria and C: Crypt of lieberkuhn.

103. Infected Rectum with treatment of Pantopeazole-Amoxicillin, a fixed dose combination for 30 days at 10 X, N: Lamina propria, M: Muscularis mucosa, E: Submucosa, and C: Crypt of lieberkuhn.

104. Infected Rectum with treatment of Pantopeazole-Amoxicillin, a fixed dose combination for 45 days at 10 X, N: Lamina propria, and C: Crypt of lieberkuhn.

105. Infected Rectum with treatment of Pantopeazole-Amoxicillin, a fixed dose combination for 60 days at 10 X, N: Lamina propria and C: Crypt of lieberkuhn.